Comparative Pharmacology
Head-to-head clinical analysis: BRIMONIDINE TARTRATE versus KAPVAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIMONIDINE TARTRATE versus KAPVAY.
BRIMONIDINE TARTRATE vs KAPVAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective alpha-2 adrenergic receptor agonist; reduces aqueous humor production and increases uveoscleral outflow by activating presynaptic alpha-2 receptors, inhibiting norepinephrine release and decreasing cAMP in ciliary epithelium.
Alpha-2 adrenergic receptor agonist; reduces sympathetic outflow from the CNS, decreasing peripheral vascular resistance and blood pressure.
1 drop of 0.1% or 0.15% solution in the affected eye(s) twice daily, approximately 12 hours apart.
0.1 mg orally twice daily, may increase by 0.1 mg/day at weekly intervals; maximum 2.4 mg/day in divided doses.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in adults; in neonates and infants, half-life may be prolonged (up to 8–12 hours) due to immature renal function.
Terminal elimination half-life 12-16 hours (range 6-24 h) in adults; prolonged in renal impairment (up to 41 h) and in neonates.
Renal excretion of unchanged drug and metabolites accounts for approximately 74% of the dose; fecal excretion accounts for approximately 22%. The remainder is eliminated via biliary secretion.
Renal: 40-60% unchanged; fecal: minimal (<10%); biliary: negligible.
Category A/B
Category C
Alpha-2 Adrenergic Agonist
Alpha-2 Adrenergic Agonist